Compare Ishares Msci Italy ETF (EWI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Merck & Co., Inc. — how do they compare? Ishares Msci Italy ETF trades at $63.13, while Merck & Co., Inc. trades at $133.5 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals.
| EWI | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $131.84 |
52-Week Low | $50.31 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI trades at $63.345, up 0.28% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The stock recently hit a 52-week high, as noted by Zacks Investment Research on June 10, 2026, amid improving industrial data and Italy's recovery narrative. A dividend of $1.17 is scheduled for June 2026, but key financial ratios like P/E and ROE are unavailable from current data.
The outlook is cautiously optimistic due to technical strength and positive sentiment, but risks include European economic volatility from ECB policy shifts and energy price fluctuations. Investors should weigh the bullish trend against potential overbought signals and macroeconomic headwinds.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
